Amphastar Pharmaceuticals Inc (AMPH)
$40.83
Insights on Amphastar Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 180.55M → 178.10M (in $), with an average decrease of 1.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 49.22M → 36.16M (in $), with an average decrease of 26.5% per quarter
Vs NBIX
In the last 1 year, Neurocrine Biosciences Inc. has given 34.1% return, outperforming this stock by 27.1%
Performance
- $40.39$41.05$40.83
1.08%
Downside
Day's Volatility :1.61%
Upside
0.54%
- $35.62$67.66$40.83
12.76%
Downside
52 Weeks Volatility :47.35%
Upside
39.65%
Returns
| Period | Amphastar Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -24.22% | 0.5% | 0.0% |
6 Months | -9.15% | 11.7% | 0.0% |
1 Year | 7.0% | 6.2% | 2.2% |
3 Years | 135.74% | 13.5% | -23.0% |
Highlights
Market Capitalization | 2.0B |
Book Value | $13.3 |
Earnings Per Share (EPS) | 2.6 |
PE Ratio | 15.77 |
PEG Ratio | 2.77 |
Wall Street Target Price | 63.25 |
Profit Margin | 21.35% |
Operating Margin TTM | 30.31% |
Return On Assets TTM | 11.07% |
Return On Equity TTM | 23.55% |
Revenue TTM | 644.4M |
Revenue Per Share TTM | 13.35 |
Quarterly Revenue Growth YOY | 31.900000000000002% |
Gross Profit TTM | 248.9M |
EBITDA | 237.7M |
Diluted Eps TTM | 2.6 |
Quarterly Earnings Growth YOY | 0.06 |
EPS Estimate Current Year | 3.62 |
EPS Estimate Next Year | 4.32 |
EPS Estimate Current Quarter | 0.91 |
EPS Estimate Next Quarter | 0.75 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 54.91%
Company Financials
| FY18 | Y/Y Change | |
|---|---|---|
Revenue | 294.7M | ↑ 22.69% |
Net Income | -5.7M | ↓ 227.28% |
Net Profit Margin | -1.95% | ↓ 3.83% |
| FY19 | Y/Y Change | |
|---|---|---|
Revenue | 322.4M | ↑ 9.4% |
Net Income | 48.9M | ↓ 952.89% |
Net Profit Margin | 15.18% | ↑ 17.13% |
| FY20 | Y/Y Change | |
|---|---|---|
Revenue | 349.8M | ↑ 8.53% |
Net Income | 1.1M | ↓ 97.76% |
Net Profit Margin | 0.31% | ↓ 14.87% |
| FY21 | Y/Y Change | |
|---|---|---|
Revenue | 437.8M | ↑ 25.13% |
Net Income | 62.1M | ↑ 5562.35% |
Net Profit Margin | 14.19% | ↑ 13.88% |
| FY22 | Y/Y Change | |
|---|---|---|
Revenue | 499.0M | ↑ 13.98% |
Net Income | 91.4M | ↑ 47.12% |
Net Profit Margin | 18.31% | ↑ 4.12% |
| FY23 | Y/Y Change | |
|---|---|---|
Revenue | 644.4M | ↑ 29.14% |
Net Income | 137.5M | ↑ 50.51% |
Net Profit Margin | 21.34% | ↑ 3.03% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 120.1M | ↓ 2.7% |
Net Income | 15.9M | ↓ 8.49% |
Net Profit Margin | 13.21% | ↓ 0.84% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 135.0M | ↑ 12.4% |
Net Income | 33.9M | ↑ 113.64% |
Net Profit Margin | 25.12% | ↑ 11.91% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 140.0M | ↑ 3.7% |
Net Income | 26.0M | ↓ 23.24% |
Net Profit Margin | 18.59% | ↓ 6.53% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 145.7M | ↑ 4.06% |
Net Income | 26.1M | ↑ 0.35% |
Net Profit Margin | 17.93% | ↓ 0.66% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 180.6M | ↑ 23.91% |
Net Income | 49.2M | ↑ 88.42% |
Net Profit Margin | 27.26% | ↑ 9.33% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 178.1M | ↓ 1.36% |
Net Income | 36.2M | ↓ 26.52% |
Net Profit Margin | 20.31% | ↓ 6.95% |
| FY18 | Y/Y Change | |
|---|---|---|
Total Assets | 513.6M | ↑ 12.95% |
Total Liabilities | 149.2M | ↑ 27.16% |
| FY19 | Y/Y Change | |
|---|---|---|
Total Assets | 587.0M | ↑ 14.29% |
Total Liabilities | 159.4M | ↑ 6.86% |
| FY20 | Y/Y Change | |
|---|---|---|
Total Assets | 631.2M | ↑ 7.54% |
Total Liabilities | 182.5M | ↑ 14.47% |
| FY21 | Y/Y Change | |
|---|---|---|
Total Assets | 671.5M | ↑ 6.38% |
Total Liabilities | 226.0M | ↑ 23.83% |
| FY22 | Y/Y Change | |
|---|---|---|
Total Assets | 742.0M | ↑ 10.49% |
Total Liabilities | 213.3M | ↓ 5.61% |
| FY23 | Y/Y Change | |
|---|---|---|
Total Assets | 1.5B | ↑ 103.9% |
Total Liabilities | 873.5M | ↑ 309.46% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 726.7M | ↑ 0.41% |
Total Liabilities | 221.5M | ↓ 1.28% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 742.0M | ↑ 2.1% |
Total Liabilities | 213.3M | ↓ 3.7% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 773.7M | ↑ 4.27% |
Total Liabilities | 225.1M | ↑ 5.51% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 1.4B | ↑ 78.15% |
Total Liabilities | 789.0M | ↑ 250.56% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 1.5B | ↑ 12.07% |
Total Liabilities | 949.5M | ↑ 20.34% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 1.5B | ↓ 2.05% |
Total Liabilities | 873.5M | ↓ 8.0% |
| FY18 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 38.2M | ↓ 2.6% |
Investing Cash Flow | -42.2M | ↑ 8.84% |
Financing Cash Flow | 25.0M | ↓ 424.02% |
| FY19 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 41.8M | ↑ 9.35% |
Investing Cash Flow | -50.5M | ↑ 19.78% |
Financing Cash Flow | -3.8M | ↓ 115.13% |
| FY20 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 57.3M | ↑ 37.12% |
Investing Cash Flow | -36.4M | ↓ 27.93% |
Financing Cash Flow | -2.2M | ↓ 40.63% |
| FY21 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 98.0M | ↑ 71.12% |
Investing Cash Flow | -28.7M | ↓ 21.26% |
Financing Cash Flow | -37.0M | ↑ 1548.17% |
| FY22 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 89.2M | ↓ 8.99% |
Investing Cash Flow | -32.8M | ↑ 14.32% |
Financing Cash Flow | -26.4M | ↓ 28.58% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 20.4M | ↑ 623.8% |
Investing Cash Flow | -15.3M | ↑ 86.53% |
Financing Cash Flow | -13.9M | ↑ 1301.51% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 15.2M | ↓ 25.27% |
Investing Cash Flow | -229.0K | ↓ 98.5% |
Financing Cash Flow | -16.2M | ↑ 16.01% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 40.4M | ↑ 165.22% |
Investing Cash Flow | -6.3M | ↑ 2665.5% |
Financing Cash Flow | -13.5M | ↓ 16.17% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 54.9M | ↑ 36.01% |
Investing Cash Flow | -508.6M | ↑ 7930.66% |
Financing Cash Flow | 428.1M | ↓ 3259.96% |
Technicals Summary
Sell
Neutral
Buy
Amphastar Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Amphastar Pharmaceuticals Inc | -5.51% | -9.15% | 7.0% | 135.74% | 89.12% |
 Neurocrine Biosciences Inc. | -2.41% | 27.65% | 34.11% | 39.49% | 77.94% |
 Haleon Plc Spon Ads | -0.12% | 5.13% | -5.51% | 13.36% | 13.36% |
 Zoetis Inc. | -7.43% | -2.98% | -11.32% | -9.68% | 48.39% |
 Viatris Inc. | -1.12% | 27.59% | 26.04% | -15.35% | -29.8% |
 Catalent, Inc. | -0.82% | 42.09% | 27.6% | -51.77% | 23.97% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Amphastar Pharmaceuticals Inc | 15.77 | 15.77 | 2.77 | 3.62 | 0.24 | 0.11 | NA | 13.3 |
Neurocrine Biosciences Inc. | 56.26 | 56.26 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 29.82 | 29.82 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.5 | 29.5 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 231.0 | 231.0 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Amphastar Pharmaceuticals Inc | Buy | $2.0B | 89.12% | 15.77 | 21.35% |
Neurocrine Biosciences Inc. | Buy | $14.1B | 77.94% | 56.26 | 13.23% |
Haleon Plc Spon Ads | Buy | $38.1B | 13.36% | 29.82 | 9.28% |
Zoetis Inc. | Buy | $68.3B | 48.39% | 29.5 | 27.43% |
Viatris Inc. | Hold | $13.7B | -29.8% | 231.0 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 23.97% | 211.02 | -31.77% |
Institutional Holdings
BlackRock Inc
12.55%Federated Hermes Inc
6.80%Vanguard Group Inc
5.85%Neuberger Berman Group LLC
3.52%State Street Corporation
3.06%Dimensional Fund Advisors, Inc.
2.78%
Company Information
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Organization | Amphastar Pharmaceuticals Inc |
Employees | 1761 |
CEO | Dr. Ziping Luo Ph.D. |
Industry | Health Technology |
